FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:140-141 January 14, 1993 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Hoffman, K. D. PubMed Citation

To the Editor: Cocconi et al. (Aug. 20 issue)¹ reported enhancement of survival in patients with metastatic malignant melanoma by some 20 weeks after treatment with dacarbazine and tamoxifen as compared with dacarbazine alone. In a cautious accompanying editorial, Guerry and Schuchter called for confirmatory studies in more uniform prognostic groups². We have examined the role of tamoxifen in enhancing chemosensitivity in a group with a particularly bad prognosis -- namely, patients with advanced malignant melanoma in whom chemotherapy has failed, a situation in which response rates are less than 10 percent.

Between March 1990 and December 1991, we . . . [Full Text of this Article]

References

Related Letters:

Error in Chemotherapy Dosages
Hoffman K. D.
Extract | Full Text  
N Engl J Med 1993; 328:1571, May 27, 1993. Correspondence

This article has been cited by other articles:

• Hoffman, K. D. (1993). Error in Chemotherapy Dosages. NEJM 328: 1571-1571 [Full Text]